prikaz prve stranice dokumenta Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157
  Download
PDF 134.13 KB
Scientific paper - Review paper
Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157
Current pharmaceutical design, 19 (2013), 1; 76-83. https://doi.org/10.2174/1381612811306010076
Sikirić, Predrag; Seiwerth, Sven; Ručman, Rudolf; Turković, Branko; Stančić-Rokotov, Dinko; Brčić, Luka; Sever, Marko; Kliček, Robert; Radić, Božo; Drmić, Domagoj; Ilić, Spomenko; Kolenc, Danijela; Aralica, Gorana; Safić, Hana; Šuran, Jelena; Rak, Davor; Džidić, Senka; Vrčić, Hrvoje; Sebečić, Božidar More authors...

Citations:
,
Cite this document

Sikirić, P., Seiwerth, S., Ručman, R., Turković, B., Stančić Rokotov, D., Brčić, L. ... Sebečić, B. (2013). Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157. Current pharmaceutical design, 19. (1), 76-83. doi: 10.2174/1381612811306010076

Sikirić, Predrag, et al. "Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157." Current pharmaceutical design, vol. 19, no. 1, 2013, pp. 76-83. https://doi.org/10.2174/1381612811306010076

Sikirić, Predrag, Sven Seiwerth, Rudolf Ručman, Branko Turković, Dinko Stančić Rokotov, Luka Brčić, Marko Sever, et al. "Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157." Current pharmaceutical design 19, no. 1 (2013): 76-83. https://doi.org/10.2174/1381612811306010076

Sikirić, P., et al. (2013) 'Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157', Current pharmaceutical design, 19(1), pp. 76-83. doi: 10.2174/1381612811306010076

Sikirić P, Seiwerth S, Ručman R, Turković B, Stančić Rokotov D, Brčić L, and sur.. Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157. Current pharmaceutical design [Internet]. 2013 January [cited 2025 April 04];19(1):76-83. doi: 10.2174/1381612811306010076

P. Sikirić, et al., "Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157", Current pharmaceutical design, vol. 19, no. 1, pp. 76-83, January 2013. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:264:282781. [Accessed: 04 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Toxicity by NSAIDs : counteraction by stable gastric pentadecapeptide BPC 157
AuthorPredrag Sikirić
AuthorSven Seiwerth
AuthorRudolf Ručman
AuthorBranko Turković
AuthorDinko Stančić-Rokotov
AuthorLuka Brčić
AuthorMarko Sever
AuthorRobert Kliček
AuthorBožo Radić
AuthorDomagoj Drmić
AuthorSpomenko Ilić
AuthorDanijela Kolenc
AuthorGorana Aralica
AuthorHana Safić
AuthorJelena Šuran
AuthorDavor Rak
AuthorSenka Džidić
AuthorHrvoje Vrčić
AuthorBožidar Sebečić
Author's institution(Merkur University Hospital)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatory bowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. We focused on BPC 157 beneficial effects on stomach, duodenum, intestine, liver and brain injuries, adjuvant arthritis, pain, hyper/hypothermia, obstructive thrombus... More formation and thrombolysis, blood vessel function, counteraction of prolonged bleeding and thrombocytopenia after application of various anticoagulants and anti-platelet agents and wound healing improvement. The arguments for BPC 157 antidote activity (i.e., the role of BPC 157 in cytoprotection, being a novel mediator of Roberts cytoprotection and BPC 157 beneficial effects on NSAID mediated lesions in the gastrointestinal tract, liver and brain and finally, counteraction of aspirin-induced prolonged bleeding and thrombocytopenia) obviously have a counteracting effect on several established side-effects of NSAID use. The mentioned variety of the beneficial effects portrayed by BPC 157 may well be a foundation for establishing BPC 157 as a NSAID antidote since no other single agent has portrayed a similar array of effects. Unlike NSAIDs, a very high safety (no reported toxicity (LD1 could be not achieved)) profile is reported for BPC 157. Also, unlike the different dosage levels of aspirin, as a NSAID prototype, which differ by a factor of about ten, all these beneficial and counteracting effects of BPC 157 were obtained using the equipotent dosage (µg, ng/kg) in parenteral or peroral regimens Less
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleCurrent pharmaceutical design
Numberingvol. 19, no. 1, pp. 76-83
p-ISSN1381-6128
DOIhttps://doi.org/10.2174/1381612811306010076
URN:NBNurn:nbn:hr:264:282781
Publication2013-01
Document URLhttp://www.eurekaselect.com/article/47225
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-12-16 11:13:00
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.